Behind XBI’s 2014 Tear

As we close out the first month of the year, 2014 is looking a lot less rosy than its predecessor. After last year brought on an insatiable bull run, it seems that markets were apprehensive to make a move higher. The last few sessions of January saw a harsh sell-off in a number of securities, with many starting the year in the red. There is one ETF, however, that has outdone many of its peers by a sizable margin, the SPDR S&P Biotech ETF (XBI). In fact, XBI is the best performing biotech ETF of the year, leaving many scratching their heads as to what lifted this ETF to such highs [for more ETF news and analysis subscribe to our free newsletter]. Underneath XBI XBI tracks an equal weight index that invests in approximately 70 biotech companies at one time. The fund has over $1.2 billion in assets under management [...] Click here to read the original article on ETFdb.com. Related Posts: 4 Yellen-Friendly ETFs ETFdb Weekly Watchlist: XHB, TLT, SPY Hinge On Housing, Fed, and GDP Data How to Use Fibonacci Extensions to Isolate Turning Points in ETFs How to Beat the S&P 500 with Style ETFs Comparing Five Years of Alternative Weighting Methodologies